RNN - Rexahn Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
1.52
-0.02 (-1.31%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.54
Open1.53
Bid1.15 x 1800
Ask0.00 x 1200
Day's Range1.50 - 1.55
52 Week Range1.35 - 3.19
Volume59,770
Avg. Volume326,306
Market Cap48.263M
Beta0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.92
Earnings DateFeb 26, 2018 - Mar 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.83
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Rexahn Announces Adjournment of Annual Meeting of Shareholders until Wednesday, June 27, 2018

    Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that its 2018 Annual Meeting of Shareholders (the “Annual Meeting”), scheduled for Thursday, June 14, 2018, was convened and Proposals 1, 2 and 4, each as set forth in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 23, 2018 (the “Proxy Statement”), were approved. The Company adjourned the Annual Meeting with respect to Proposal 3, a proposal to amend its amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000 shares.  While Proposal 3 has received the support of the majority of shares voting on the proposal, approval of more than 50% of all outstanding shares of Rexahn common stock as of April 18, 2018 is necessary for the proposal to be approved.

  • GlobeNewswirelast month

    Rexahn Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

    Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that preliminary data from a Phase 2a clinical trial of RX-5902 in metastatic triple negative breast cancer (TNBC) and updated data from the Phase 2a trial of RX-3117 in advanced bladder cancer were presented at the American Society of Clinical Oncology (ASCO) 2018 annual meeting on June 2, 2018. “We are encouraged by the data presented at ASCO including a complete response in advanced bladder cancer in a patient being treated with RX-3117.

  • GlobeNewswire2 months ago

    Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage

    Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, advances its ongoing Phase 2a study of RX-3117 in combination with Abraxane® in first-line patients with metastatic pancreatic cancer following a recently completed routine Safety Monitoring Committee (SMC) review. The SMC has confirmed that the combination of RX-3117 and Abraxane is safe and well tolerated and that the two drugs can be given in combination at the highest recommended doses for both agents which is once-daily oral administration of 700 mg RX-3117 five times per week plus once-weekly Abraxane® at 125 mg/m2 IV given on a three weeks on/one week off per four-week cycle schedule.

  • GlobeNewswire2 months ago

    Rexahn Reports First Quarter 2018 Financial Results

    ROCKVILLE, Md., May 07, 2018-- Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, announced financial results ...

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within PTC, Black Hills, Mack-Cali Realty, Milacron, Rexahn Pharmaceuticals, and Sunoco LP — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, May 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PTC ...

  • GlobeNewswire3 months ago

    Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

    Preliminary Safety and Efficacy Data from Phase 1 b/2a Trial of RX-5902 in Advanced Triple Negative Breast Cancer. Updated Safety and Efficacy Data on RX-3117 in Advanced Urothelial Cancer. ROCKVILLE, ...

  • Rexahn Pharmaceuticals, Inc. Secures First US Patent For Its Anticancer Drug Candidate
    SmarterAnalyst6 months ago

    Rexahn Pharmaceuticals, Inc. Secures First US Patent For Its Anticancer Drug Candidate

    Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/255,901, "Quinoxalinyl Piperazinamide Methods of Use".  The allowed patent application covers the use of RX-5902, also known as Supinoxin for the treatment of cancers including triple negative breast cancer either as monotherapy or in combination with other anti-tumor agents such as cytotoxic agents or immune checkpoint inhibitors. The allowed application will extend the patent protection for uses claimed under this patent until 2036.

  • ACCESSWIRE8 months ago

    Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Idera Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 7, 2017 / U.S. markets once again reached record highs on Monday on news of merger deals within the tech industry and continued strength in corporate earnings. The ...

  • Associated Press8 months ago

    Rexahn reports 3Q loss

    The Rockville, Maryland-based company said it had a loss of 4 cents per share. Losses, adjusted for non-recurring gains, came to 15 cents per share. The results topped Wall Street expectations. The average ...